FDA Approves TEGRETOL — Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation announced today that the U.S. FDA has approved generic versions of Tegretol (carbamazepine), signaling potential new competitive pricing pressure and shifting market dynamics for this long-established anticonvulsant in the treatment of epilepsy and neuropathic pain. While Tegretol established the brand following its initial 1987 launch, the availability of the generic formulation may threaten the legacy drug’s market share and revenue stream as payers incentivize the use of lower-cost therapeutic options.